A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer
The addition of atezolizumab to pertuzumab plus high-dose trastuzumab does not result in improved CNS responses in patients with HER2-positive breast cancer brain metastases.
Authors
- Raechel Davis
- Qingchun Jin (ORCID: https://orcid.org/0000-0001-6388-5123)
- Laura Sharp
- Elizabeth A. Mittendorf (ORCID: https://orcid.org/0000-0002-9762-8536)
- Tianyu Li (ORCID: https://orcid.org/0000-0001-9856-9657)
- Molly K. DiLullo (ORCID: https://orcid.org/0009-0005-1036-796X)
- Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
- Alyssa Pereslete (ORCID: https://orcid.org/0000-0001-7995-7507)
- José Pablo Leone (ORCID: https://orcid.org/0000-0002-8537-652X)
- Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
- Siyang Ren (ORCID: https://orcid.org/0000-0003-1495-7199)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Eric P. Winer (ORCID: https://orcid.org/0000-0002-8819-1723)
- Busem Binboğa Kurt (ORCID: https://orcid.org/0000-0002-7161-1496)
- Erica L. Mayer (ORCID: https://orcid.org/0000-0001-5430-8957)
- Priya Kumthekar (ORCID: https://orcid.org/0000-0001-5923-0677)
- Antonio Giordano (ORCID: https://orcid.org/0000-0002-7760-9717)
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Northwestern Memorial Hospital (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1161
- Citations
- 8
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Breast Cancer Research Foundation
- Genentech